A practical reference on dual agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-12 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
=== Tolerance dose === In 1931, the U.S. Advisory Committee on X-Ray and Radium Protection (ACXRP, now the National Council on Radiation Protection and Measurements, NCRP), founded in 1929, published the results of a study on the so-called tolerance dose, on which a scientifically based radiation protection guideline was based. Exposure limits were gradually lowered. In 1936 the tolerance dose was 0.1 R/day. The unit "R" (the X-ray) from the CGS unit system has been obsolete since the end of 1985. Since then, the SI unit of ion dose has been "coulomb per kilogram".
=== Traditional medicines === Parmotrema perlatum is used as a component of a herbal mixture in Ayurvedic medicine, one of several parmelioid lichen species used as charila. Referenced in ancient Ayurvedic texts and first mentioned in the Atharvaveda around 1500 BCE, charila is a lichen mixture traditionally used in India for its purported medicinal properties. It has been employed to treat various ailments, including digestive and respiratory issues, skin conditions, and reproductive health concerns, and it also serves as an ingredient in treatments for infertility. For chronic ulcers, a powder made from dried lichen, infused in pork suet, is applied externally.
The parties will proceed to close the transaction in which funds and title are exchanged. When a deal closes, post-closing processes may begin, including notifying tenants of an ownership change, transferring vendor relationships, and handing over relevant information to the asset management team.
Sources: en.wikipedia.org
== History == Earl W. McDaniel has been called the father of ion mobility mass spectrometry. In the early 1960s, he coupled a low-field ion mobility drift cell to a sector mass spectrometer. The combination of time-of-flight mass spectrometry and ion mobility spectrometry was pioneered in 1963 at Bell Labs. In 1963 McAfee and Edelson published an IMS-TOF combination. In 1967 McKnight, McAfee and Sipler published an IMS-TOF combination. Their instrument included an orthogonal TOF. In 1969 Cohen et al. filed a patent on an IMS-QMS system. The QMS at that time was an improvement compared to the TOFMS, because the TOFMS had a slow electronic data acquisition systems at that time. In 1970, Young, Edelson and Falconer published an IMS-TOF with orthogonal extraction. They seem to have used the same system as McKnight et al. in 1967, incorporating slight modifications. Their work was later reproduced in the landmark book of Mason/McDaniel, which is regarded as the "bible of IMS" by those skilled in the art. In 1996 Guevremont et al. presented a poster at the ASMS conference about IMS-TOF. In 1997 Tanner patented a quadrupole with axial fields which can be used as a drift cell for IMS separation. He also mentions the combination of these quadrupoles with an orthogonal TOFMS. In 1998 Clemmer developed an IMS-TOF combination, using a co-axial IMS-TOF setup. In 1999 Clemmer developed an IMS-TOF with an orthogonal TOF system.
== See also == Substituted phenylethylpyrrolidine α-Pyrrolidinopropiophenone (α-PPP) α-Pyrrolidinobutiophenone (α-PBP) α-Pyrrolidinopentiophenone (α-PVP) α-Pyrrolidinohexiophenone (α-PHP) α-Pyrrolidinoheptaphenone (α-PHPP)
=== Early indications === The syntheses of elements 107 to 112 were conducted at the GSI Helmholtz Centre for Heavy Ion Research in Darmstadt, Germany, from 1981 to 1996. These elements were made by cold fusion reactions, in which targets made of lead and bismuth, which are around the stable configuration of 82 protons, are bombarded with heavy ions of period 4 elements. This creates fused nuclei with low excitation energies due to the stability of the targets' nuclei, significantly increasing the yield of superheavy elements. Cold fusion was pioneered by Yuri Oganessian and his team in 1974 at the Joint Institute for Nuclear Research (JINR) in Dubna, Soviet Union. Yields from cold fusion reactions were found to decrease significantly with increasing atomic number; the resulting nuclei were severely neutron-deficient and short-lived. The GSI team attempted to synthesise element 113 via cold fusion in 1998 and 2003, bombarding bismuth-209 with zinc-70; both attempts were unsuccessful. Faced with this problem, Oganessian and his team at the JINR turned their renewed attention to the older hot fusion technique, in which heavy actinide targets were bombarded with lighter ions. Calcium-48 was suggested as an ideal projectile, because it is very neutron-rich for a light element (combined with the already neutron-rich actinides) and would minimise the neutron deficiencies of the nuclides produced. Being doubly magic, it would confer benefits in stability to the fused nuclei.
Recipes intended for other cooking methods must be modified for slow cookers. Quantities of liquids may need adjustment, as there is a little evaporation, but there should be enough liquid to cover the food. Many published recipes for slow cookers are designed primarily for convenience and use few ingredients, and often use prepared sauces or seasonings. The long, moist cooking is particularly suitable for tough and cheap cuts of meat including pork shoulder, chuck steak and brisket. For many slow-cooked dishes, these cuts give better results than more expensive ones. They are also often used to cook while unattended, meaning the cook can fill the pot with its ingredients and come back several hours later to a ready meal.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.